Cabozantinib Earns CHMP Recommendation in Pancreatic Neuroendocrine Tumors
The drug Cabozantinib has received a positive recommendation from CHMP for its application in the treatment of pancreatic neuroendocrine tumors.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
The Food and Drug Administration (FDA) has issued a partial hold on clinical trials involving the drug Lorigerlimab for its proposed use in the treatment of gynecologic cancers.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
In the fight against Melanoma, breakthrough findings pave the way for improved management of toxicities stemming from immune-checkpoint inhibitors.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
SRN-101 has earned a fast-track designation by the FDA for its potential to deliver therapeutic results in recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Exciting developments point to a novel small molecule revealing early activity in combatting pretreated Multiple Myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
Recent studies provide an insightful comparison into quality of life outcomes regarding the implementation of protons versus photons in the treatment of OPSCC.
